Prostatype Genomics AB (PGO0) AI Stock Analysis

1 Followers

Prostatype Genomics AB

(Frankfurt:PGO0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Focused precision-medicine businessThe company operates in a focused precision-medicine niche, using genomic and biomarker analysis to support prostate-cancer treatment decisions. A specialized diagnostic offering can create durable clinical relevance if adoption expands, because risk assessment and treatment guidance are recurring healthcare needs.

Negative Factors

Severe unprofitabilityDeeply negative gross, operating, and net margins show that current revenue does not cover the economics of the business. Unless pricing, delivery economics, or operating efficiency improve materially, persistent losses will constrain reinvestment and weaken the path to sustainable profitability.

Prostatype Genomics AB (PGO0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.07M
Dividend Yield: ―
Average Volume (3M): 3,888
Price to Earnings (P/E): -0.2
Beta (1Y): -2.64
Revenue Growth: 150.61%
EPS Growth: 69.81%
Country: Germany
Employees: 7
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Sc...

Prostatype Genomics AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PGO0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:DVYSR	66Neutral	SEK 1.13B	42.76	―	―	4.49%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:QLINEA	43Neutral	SEK 263.39M	-1.53	-48.10%	―	33.26%	90.73%
SE:ACARIX	42Neutral	SEK 200.71M	-5.36	-96.06%	―	40.61%	32.63%
SE:BIOVIC.B	41Neutral	SEK 93.57M	-1.24	-75.51%	―	56.06%	63.95%
SE:IMMNOV	33Underperform	SEK 85.00M	-0.28	-215.44%	―	148.66%	66.30%

* Healthcare Sector Average

Performance Comparison

DE:PGO0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PGO0	Prostatype Genomics AB	0.01	-0.00	-28.57%
SE:IMMNOV	Immunovia AB	0.03	-0.18	-84.69%
SE:QLINEA	Q-linea AB	13.25	-11.87	-47.25%
SE:ACARIX	Acarix AB	0.17	-0.10	-37.04%
SE:BIOVIC.B	Biovica International AB Class B	0.31	-0.24	-44.20%
SE:DVYSR	Devyser Diagnostics AB	65.00	-48.60	-42.78%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Prostatype Genomics AB AI Stock Analysis